| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $10,099,433 | 29 | 100 |
| Wright Christopher I | director | 0 | $0 | 1 | $90,200 | $-90,200 |
| Nichols Christian Todd | SVP, Chief Commercial Officer | 0 | $0 | 2 | $552,937 | $-552,937 |
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | 0 | $0 | 10 | $829,288 | $-829,288 |
| Parisi Samuel Joseph | VP, Finance (Interim PAO) | 0 | $0 | 2 | $888,815 | $-888,815 |
| Cooke Shane | director | 0 | $0 | 1 | $2.12M | $-2.12M |
| snyderman nancy lynn MD | director | 0 | $0 | 1 | $2.24M | $-2.24M |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | 0 | $0 | 13 | $3.66M | $-3.66M |
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an …
Over the last 12 months, insiders at Alkermes plc have bought $0 and sold $10.1M worth of Alkermes plc stock.
On average, over the past 5 years, insiders at Alkermes plc have bought $412,870 and sold $8.57M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 35,000 shares for transaction amount of $815,735 was made by Daglio David Angelo Jr. (director) on 2022‑11‑14.
| 2026-11-03 | Sale | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | 2,035 0.0012% | $46.17 | $93,956 | -1.04% | |
| 2026-10-02 | Sale | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | 2,034 0.0012% | $41.03 | $83,455 | +3.53% | |
| 2026-09-03 | Sale | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | 2,034 0.0012% | $48.01 | $97,652 | -7.35% | |
| 2026-09-01 | Sale | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | 9,000 0.0053% | $46.99 | $422,874 | -7.72% | |
| 2026-08-17 | Sale | Nichols Christian Todd | SVP, Chief Commercial Officer | 7,576 0.0045% | $49.23 | $372,937 | -10.85% | |
| 2026-08-03 | Sale | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | 2,034 0.0012% | $48.58 | $98,812 | -8.34% | |
| 2026-08-03 | Sale | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | 9,000 0.0053% | $48.58 | $437,220 | -8.34% | |
| 2026-08-03 | Sale | snyderman nancy lynn MD | director | 44,472 0.0271% | $50.35 | $2.24M | -8.34% | |
| 2026-07-06 | Sale | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | 2,034 0.0012% | $54.03 | $109,897 | -14.98% | |
| 2026-07-01 | Sale | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | 9,000 0.0053% | $51.51 | $463,621 | -9.15% | |
| 2026-06-12 | Sale | Wright Christopher I | director | 2,000 0.0012% | $45.10 | $90,200 | +6.59% | |
| 2026-06-04 | Sale | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | 2,034 0.0012% | $43.05 | $87,564 | +7.68% | |
| 2026-06-01 | Sale | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | 9,000 0.0053% | $41.67 | $375,044 | +9.07% | |
| 2026-05-29 | Sale | Parisi Samuel Joseph | VP, Finance (Interim PAO) | 16,217 0.0103% | $42.36 | $687,007 | +9.27% | |
| 2026-05-04 | Sale | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | 2,034 0.0012% | $33.20 | $67,529 | +32.78% | |
| 2026-05-01 | Sale | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | 9,000 0.0054% | $33.40 | $300,560 | +35.87% | |
| 2026-04-06 | Sale | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | 2,034 0.0012% | $34.57 | $70,315 | +29.96% | |
| 2026-04-01 | Sale | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | 9,000 0.0055% | $35.51 | $319,604 | +26.33% | |
| 2026-03-03 | Sale | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | 2,034 0.0012% | $29.76 | $60,532 | +47.71% | |
| 2026-03-02 | Sale | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | 2,034 0.0012% | $29.29 | $59,576 | +42.05% |
| snyderman nancy lynn MD | director | 15395 0.0092% | $703,397.55 | 1 | 1 | +14% |
| BLOOM FLOYD E | director | 127923 0.0763% | $5.84M | 1 | 13 | +9.38% |
| Daglio David Angelo Jr. | director | 80000 0.0477% | $3.66M | 1 | 0 | +23.43% |
| ANSTICE DAVID W | director | 73081 0.0436% | $3.34M | 1 | 4 | +44.33% |
| Stejbach Mark | SVP/Chief Comm Off, Alks Inc | 44013 0.0262% | $2.01M | 1 | 9 | +46.24% |
| DIXON WENDY L | director | 41300 0.0246% | $1.89M | 1 | 2 | +1.23% |
| Wysenski Nancy | director | 15829 0.0094% | $723,227.01 | 3 | 1 | <0.0001% |
| MCKEON BRIAN P | director | 10000 0.006% | $456,900.00 | 1 | 0 | +4.55% |
| Alva Emily Peterson | director | 1650 0.001% | $75,396.04 | 1 | 0 | <0.0001% |
| Increased Positions | 252 | +50.81% | 52M | +20.51% |
| Decreased Positions | 226 | -45.56% | 48M | -19.27% |
| New Positions | 90 | New | 28M | New |
| Sold Out Positions | 73 | Sold Out | 22M | Sold Out |
| Total Postitions | 522 | +5.24% | 255M | +1.23% |
| Blackrock, Inc. | $790,491.00 | 16.95% | 27.97M | +115,915 | +0.42% | 2025-09-30 |
| Vanguard Group Inc | $513,753.00 | 11.02% | 18.18M | -323,563 | -1.75% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $289,336.00 | 6.21% | 10.24M | +196,457 | +1.96% | 2025-09-30 |
| State Street Corp | $241,350.00 | 5.18% | 8.54M | +332,095 | +4.05% | 2025-09-30 |
| Baker Bros. Advisors Lp | $228,662.00 | 4.9% | 8.09M | +2M | +26.22% | 2025-09-30 |
| Renaissance Technologies Llc | $177,827.00 | 3.81% | 6.29M | +482,368 | +8.3% | 2025-09-30 |
| American Century Companies Inc | $124,273.00 | 2.67% | 4.4M | +740,248 | +20.24% | 2025-09-30 |
| Geode Capital Management, Llc | $114,775.00 | 2.46% | 4.06M | +37,842 | +0.94% | 2025-09-30 |
| Jpmorgan Chase & Co | $111,010.00 | 2.38% | 3.93M | -908,124 | -18.78% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $104,505.00 | 2.24% | 3.7M | +601,359 | +19.42% | 2025-09-30 |